{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=20",
    "query": {
      "condition": "Carcinoma, Bronchogenic",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 3584,
    "total_pages": 359,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T02:57:56.087Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01562015",
      "title": "A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Ganetespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synta Pharmaceuticals Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2012-04",
      "completion_date": "2014-11",
      "has_results": false,
      "last_update_posted_date": "2015-05-20",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida • Cleveland, Ohio",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01562015"
    },
    {
      "nct_id": "NCT01031225",
      "title": "A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "STA 9090",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synta Pharmaceuticals Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 113,
      "start_date": "2009-11",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-09-19",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 21,
      "location_summary": "Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 15 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01031225"
    },
    {
      "nct_id": "NCT03194893",
      "title": "A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 50,
      "start_date": "2017-07-05",
      "completion_date": "2025-09-18",
      "has_results": true,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 2,
      "location_summary": "Orange, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03194893"
    },
    {
      "nct_id": "NCT00499655",
      "title": "Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Stage IV Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "fluorescence in situ hybridization",
          "type": "GENETIC"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "protein expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "GENETIC"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2007-11",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 2,
      "location_summary": "Duarte, California • South Pasadena, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499655"
    },
    {
      "nct_id": "NCT04644315",
      "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms",
        "Colorectal Neoplasms",
        "Melanoma",
        "Pancreatic Neoplasms",
        "Sarcoma",
        "Ovarian Neoplasms",
        "Brain Neoplasms",
        "Thyroid Neoplasms",
        "Neuroendocrine Tumors",
        "Cholangiocarcinoma",
        "Salivary Gland Neoplasms",
        "Head and Neck Neoplasms",
        "Thyroid Cancer, Papillary",
        "Lymphoma, Large-Cell, Anaplastic",
        "Neoplasms by Site",
        "Respiratory Tract Neoplasms",
        "Thoracic Neoplasms",
        "Respiratory Tract Diseases",
        "Carcinoma, Bronchogenic",
        "Bronchial Neoplasms",
        "Intestinal Neoplasms",
        "Gastrointestinal Neoplasms",
        "Digestive System Neoplasms",
        "Digestive System Diseases",
        "Gastrointestinal Diseases",
        "Colonic Diseases",
        "Intestinal Diseases",
        "Central Nervous System"
      ],
      "interventions": [
        {
          "name": "Alectinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-05-24",
      "completion_date": "2022-05-16",
      "has_results": true,
      "last_update_posted_date": "2023-08-07",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 29,
      "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04644315"
    },
    {
      "nct_id": "NCT07339176",
      "title": "Intratumoral N17350 in Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Solid Tumor",
        "Breast Neoplasms, Triple-Negative",
        "Squamous Cell Carcinoma of Skin",
        "Melanoma",
        "Head and Neck Neoplasms",
        "Carcinoma, Squamous Cell",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "N17350",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Onchilles Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 275,
      "start_date": "2026-05-25",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07339176"
    },
    {
      "nct_id": "NCT03752398",
      "title": "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma (Excluding Uveal Melanoma)",
        "Cervical Carcinoma",
        "Pancreatic Carcinoma",
        "Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative",
        "Hepatocellular Carcinoma",
        "Urothelial Carcinoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Nasopharyngeal Carcinoma",
        "Renal Cell Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Non-small Cell Lung Carcinoma",
        "Small Cell Lung Cancer",
        "Gastric or Gastroesophageal Junction Adenocarcinoma",
        "Advanced Solid Tumors",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "XmAb®23104",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Yervoy® (ipilimumab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Xencor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 198,
      "start_date": "2019-05-01",
      "completion_date": "2024-02-15",
      "has_results": false,
      "last_update_posted_date": "2024-07-05",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 18,
      "location_summary": "San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03752398"
    },
    {
      "nct_id": "NCT02650635",
      "title": "TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Adenocarcinoma",
        "Metastatic Pancreatic Adenocarcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Melanoma of the Skin",
        "Recurrent Non-Small Cell Lung Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Renal Cell Carcinoma",
        "Solid Neoplasm",
        "Stage IV Breast Cancer",
        "Stage IV Non-Small Cell Lung Cancer",
        "Stage IV Renal Cell Cancer",
        "Stage IV Skin Melanoma",
        "Stage IVA Colorectal Cancer",
        "Stage IVA Pancreatic Cancer",
        "Stage IVB Colorectal Cancer",
        "Stage IVB Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "TLR8 Agonist VTX-2337",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2016-02-05",
      "completion_date": "2017-06-01",
      "has_results": false,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02650635"
    },
    {
      "nct_id": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Colorectal Cancer",
        "Breast Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Head and Neck Cancer",
        "GastroEsophageal Cancer"
      ],
      "interventions": [
        {
          "name": "FT536",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nivolumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Atezolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Trastuzumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cetuximab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Amivantamab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Fate Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2022-05-31",
      "completion_date": "2023-08-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05395052"
    },
    {
      "nct_id": "NCT00525148",
      "title": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "BIBW 2992",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 129,
      "start_date": "2007-08",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-16",
      "last_synced_at": "2026-10-15T02:57:56.087Z",
      "location_count": 23,
      "location_summary": "Bakersfield, California • Beverly Hills, California • Mission Hills, California + 19 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00525148"
    }
  ]
}